1. Introduction

Biotechnology valuation is the process of determining the economic value of a biotechnology company, its intellectual property (IP), patents, biological products, research and development (R&D) pipeline, licensing rights, clinical-stage assets, manufacturing capabilities, and related commercial opportunities.

Unlike conventional businesses, biotech companies often derive most of their value from assets that are uncertain, difficult to reproduce, and dependent on regulatory approvals, scientific results, patent protection, and future commercialisation.

The legal dimension of biotech valuation is important in:

Mergers and acquisitions (M&A) and corporate restructuring.

Venture capital, private equity, and public-market fundraising.

Patent licensing, technology transfers, and royalty negotiations.

Pharmaceutical and biologic product development.

Insolvency, liquidation, and creditor disputes.

Taxation, transfer pricing, and related-party transactions.

Litigation involving patent infringement, ownership, fraud, or misleading valuations.

The central legal question is whether the valuation methodology is reasonable, adequately supported by evidence, consistent with applicable law, and based on accurate assumptions concerning the rights and risks attached to the biotech assets.

This explanation focuses primarily on Indian law, with relevant United States, United Kingdom, and Australian authorities for comparative analysis. Case-law applicability depends on the transaction, jurisdiction, and governing law.

2. Principal legal considerations in biotech valuation

Intellectual property ownership

Patent validity, inventorship, employee inventions, university rights, licensing restrictions, and freedom to operate determine whether the company actually controls the technology being valued.

Regulatory and clinical risk

Clinical-trial status, product approvals, manufacturing standards, safety obligations, and regulatory exclusivity affect expected revenue and the probability of commercial success.

Corporate and transaction law

Company law, shareholder rights, securities disclosures, merger approvals, related-party transactions, and contractual representations constrain how the valuation may be used.

Financial methodology and evidence

Discounted cash flow (DCF), comparable transactions, milestone-adjusted valuation, and probability-weighted forecasts must reflect defensible assumptions rather than speculative claims.

3. Statutory framework under Indian law

3.1 Companies Act, 2013 — Section 247

Section 247 is a central provision where valuation is required under the Companies Act. It requires a registered valuer with appropriate qualifications and experience, appointed by the audit committee or, where there is no audit committee, the board of directors.

The valuer must:

Conduct an impartial, true, and fair valuation.

Exercise due diligence.

Comply with the applicable valuation rules.

Avoid prohibited conflicts of interest.

Contraventions may lead to monetary penalties, and where the statutory conditions involving fraudulent intent are satisfied, imprisonment and additional financial consequences may follow. The provision also addresses refund of remuneration and damages following conviction for qualifying misconduct.

IndiaCode+1

Application to biotech: If a company values a biologic-drug pipeline, proprietary cell line, patent portfolio, or other intangible assets for a transaction governed by the Companies Act, the valuation must reflect the actual legal rights and their economic prospects.

A valuation report should identify the assets valued, the valuation date, methodology, assumptions, material risks, and supporting evidence.

3.2 Companies (Registered Valuers and Valuation) Rules, 2017

These Rules establish the registration and professional framework for valuers under Section 247. The applicable registration requirements and asset-class rules must be considered when selecting the professional who prepares the valuation.

Biotech assets create a practical difficulty: scientific expertise and valuation competence are different disciplines. A registered valuer may need support from patent counsel, clinical experts, regulatory specialists, and financial analysts.

For example, a financial analyst might project substantial revenue from an antibody drug, but a patent expert may conclude that the relevant claims are vulnerable to invalidation. The final valuation should incorporate that legal risk rather than simply accepting the revenue forecast.

The Insolvency and Bankruptcy Board of India provides information on the registered-valuer framework and valuation examinations.

IBBI+1

3.3 Companies Act provisions governing transactions

Depending on the transaction, additional provisions may apply:

These provisions do not create one universal valuation method. The relevant requirements depend on the transaction structure, the company's status, applicable rules, and any exemptions.

For listed companies, the Securities and Exchange Board of India (SEBI) framework may also impose additional disclosure, pricing, independent valuation, or transaction-related obligations.

3.4 Income-tax and transfer-pricing considerations

Biotech valuation may determine the tax treatment of a patent transfer, an international licence, a related-party R&D arrangement, or a cross-border transfer of technology.

Relevant issues include:

Whether the transaction reflects an arm's-length price.

Whether royalties are commercially supportable.

Whether R&D contributions and economically significant functions have been properly considered.

Whether the transaction transfers legal ownership, economic rights, or both.

Whether tax rules require a prescribed valuation method or supporting documentation.

A licence between related companies may be challenged if the royalty rate lacks a defensible commercial basis. Conversely, a high royalty is not automatically improper merely because the underlying product is innovative.

The correct approach is to assess the rights transferred, territorial scope, exclusivity, remaining patent term, development obligations, and the parties' actual contributions.

4. Intellectual property law and biotech valuation

Intellectual property is often the most important component of biotech enterprise value.

However, the existence of a patent does not automatically establish that the patented technology is valid, enforceable, commercially useful, or free from competing rights.

4.1 Patent validity and enforceability

A valuation should examine:

Patent ownership and chain of title.

Inventorship and assignments.

Remaining patent term.

Claim scope and enforceability.

Existing oppositions, revocation proceedings, and infringement litigation.

Prior-art and patentability risks.

Patent-family coverage in commercially important countries.

Freedom-to-operate risks involving third-party patents.

A patent may have substantial scientific value but limited commercial value if the claims are narrow, the remaining term is short, or competing rights restrict commercialisation.

4.2 Indian patent law

The Patents Act, 1970, is particularly relevant to biotech valuations.

Section 3(c) excludes certain discoveries of living things or non-living substances occurring in nature from patentability. Section 3(d) restricts patentability of certain new forms of known substances unless the statutory requirements are satisfied. Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, as well as essentially biological processes for production or propagation of plants and animals.

These exclusions can materially affect the valuation of genetic discoveries, biological materials, plant biotechnology, and pharmaceutical inventions.

A legal due-diligence exercise must distinguish between an invention that is technically promising and one that can actually receive or sustain the required patent protection.

5. Leading case laws and their relevance to biotech valuation

The following judgments do not all concern valuation directly. They establish legal principles that affect the value, enforceability, or commercial exploitation of biotech assets.

5.1 Novartis AG v. Union of India (2013)

Supreme Court of India · (2013) 6 SCC 1 · Judgment dated 1 April 2013

Facts: Novartis sought patent protection in India for the beta-crystalline form of imatinib mesylate, associated with the anticancer medicine Glivec.

Legal issue: Whether the claimed form satisfied the applicable patentability requirements, particularly Section 3(d) of the Patents Act, 1970.

Decision: The Supreme Court upheld rejection of the patent application, finding that the claimed form did not establish the enhanced therapeutic efficacy required under Section 3(d).

Indian Kanoon+1

Relevance to valuation:

A drug's commercial success does not itself establish that every related patent claim is valid.

Patentability risks must be reflected in the projected period of exclusivity.

Revenue forecasts should distinguish between protected products and products that may face generic competition.

Claims concerning new forms of known substances require scrutiny of the applicable statutory requirements.

Practical example: A company forecasts ten years of high-margin sales for a modified formulation of an established drug. If the relevant Indian patent application is rejected, the valuation may need to be reduced to reflect earlier competition, subject to other valid rights, regulatory exclusivities, and market circumstances.

5.2 Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

Supreme Court of India · (2019) 3 SCC 381 · Judgment dated 8 January 2019

Facts: The dispute concerned Monsanto's patented Bt cotton technology, licensing arrangements, and the interaction between patent protection and plant-variety law.

Legal issue: The dispute involved the enforceability and treatment of biotechnology patent rights, including challenges connected with Section 3(j) of the Patents Act.

Decision: The Supreme Court set aside the Delhi High Court's challenged judgment and remanded the matter for fresh consideration, holding that the complex patent-validity issues were not appropriately resolved through the summary process used below. It should not be treated as a final determination that all the disputed patent claims were valid or invalid.

Sci API+1

Relevance to valuation:

Agricultural biotechnology valuations must consider the interaction between patents, plant-variety protection, seed regulations, and licensing rules.

Licensing income may be affected by enforceability disputes and restrictions on contractual royalty arrangements.

A valuation should account for pending litigation rather than treating projected royalties as certain.

Contractual rights to use a technology must be assessed separately from ownership of the underlying invention.

Practical example: A company receives trait-licensing fees from seed manufacturers. If litigation threatens the enforceability or scope of the underlying rights, the expected royalty stream should be probability-adjusted.

5.3 Amgen Inc. v. Sanofi (2023)

Supreme Court of the United States · 598 U.S. 594 (2023) · Judgment dated 18 May 2023

Facts: Amgen asserted patents covering a broad class of antibodies that bind to PCSK9 and block its interaction with LDL receptors. Sanofi challenged the patents on enablement grounds.

Legal issue: Whether the patent disclosure enabled the full scope of the claimed antibody class under 35 U.S.C. §112(a).

Decision: The Supreme Court upheld the conclusion that the patent claims at issue were insufficiently enabled. A patent claiming a class of inventions must enable skilled persons to make and use the full scope of that class, although reasonable experimentation may be permissible depending on the technology.

Supreme Court+1

Relevance to valuation:

This case is particularly important for antibody therapeutics, protein engineering, and platform-biotechnology companies.

A company may possess substantial research data but still face patent risk if its claims cover far more than its disclosure teaches. Investors should therefore examine:

The breadth of the claims compared with the disclosed embodiments.

Whether the technology can be reproduced without excessive experimentation.

The extent to which the commercial product falls within enforceable claims.

Whether competing companies can develop alternative molecules outside the claims.

Valuation principle: Broad patent claims should not automatically be assigned a higher value than narrow claims. Their value depends on the likelihood that the breadth will survive legal scrutiny and provide meaningful commercial protection.

5.4 Diamond v. Chakrabarty (1980)

Supreme Court of the United States · 447 U.S. 303 (1980)

Facts: The case concerned a genetically engineered microorganism capable of breaking down components of crude oil.

Legal issue: Whether the engineered microorganism constituted patentable subject matter under the United States Patent Act.

Decision: The Court held that the genetically engineered microorganism at issue fell within patent-eligible subject matter under the applicable US statute. Diamond v. Chakrabarty is a foundational decision in modern biotechnology patent law.

Relevance to valuation:

The case illustrates the commercial importance of protectable engineered organisms and biological technologies. However, patent eligibility is only one part of the analysis: novelty, non-obviousness, disclosure, ownership, regulatory permission, and enforceability remain separate questions.

The judgment is a US authority, not a rule that automatically governs patentability in India.

5.5 Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576 (2013)

Facts: The litigation concerned patents relating to BRCA1 and BRCA2 genes associated with breast and ovarian cancer risk.

Legal issue: Whether naturally occurring DNA sequences isolated from the human genome were patentable merely because they had been isolated.

Decision: The Court held that naturally occurring DNA was not patent-eligible merely because it had been isolated, while synthetically created cDNA could be patent-eligible subject to the relevant circumstances. Association for Molecular Pathology v. Myriad Genetics.

Relevance to valuation:

A diagnostic-testing or genomic-research company's valuation may depend on whether its competitive advantage comes from patentable inventions, proprietary datasets, laboratory know-how, software, or commercial services.

If a company's business model depends on exclusive control over naturally occurring genetic sequences, its valuation assumptions must be reviewed against the applicable jurisdiction's patent law.

5.6 Comparative lessons from the cases

These cases show that legal protection is an economic input into valuation, not a substitute for financial analysis.

6. Legal valuation methods for biotechnology assets

No single valuation method is appropriate for every biotech asset. The method should match the asset's development stage, available data, legal rights, and commercial purpose.

Medical Science Laboratory. Scientists Working in Advanced Scientific Pharmaceutical Lab for Medicine, Biotechnology Development

A. Discounted cash flow (DCF)

Estimates the present value of expected future cash flows, discounted for time and risk.

Best suited to assets with reasonably estimable future revenue, such as approved biologics or established diagnostic products.

Legal concern: Revenue forecasts must account for patent expiry, licensing restrictions, regulatory obligations, and litigation.

Novo Nordisk inngår samarbeid med OpenAI for å akselerere AI i legemiddelutvikling

B. Probability-adjusted valuation

Estimates future revenue or cash flow while accounting for the probability of scientific, clinical, regulatory, and commercial success.

Particularly useful for preclinical drugs and clinical-stage pipelines.

Legal concern: Probabilities should reflect the actual development stage and applicable approval requirements, not merely management optimism.

The First Patented G.M.O. - Asimov Press

C. Relief-from-royalty method

Estimates the royalties a business would hypothetically pay to license an asset it owns, then discounts the after-tax royalty savings.

Often used for patents, trademarks, proprietary processes, and certain licensed technologies.

Legal concern: The royalty rate must reflect the actual rights, territorial coverage, exclusivity, remaining term, and comparable licensing evidence.

The HealthTech Founder’s Guide to Investor-Ready Pitches: Three Critical Mistakes and How to Fix Them

D. Market and comparable-transaction method

Uses relevant transactions involving comparable companies, products, patents, or licences.

Legal concern: Differences in patent portfolios, litigation exposure, clinical status, geography, and regulatory exclusivity must be adjusted.

Illustrative probability-adjusted valuation

Suppose a biotech company is developing a new therapeutic biologic and its forecast commercial cash flows have an estimated present value of ₹500 crore if the product succeeds.

Assume the probability of commercial success is 30%, and the present value of remaining development expenditure is ₹40 crore.

A simplified calculation is:

\[ \begin{aligned} \text{Risk-adjusted value} &= ₹500 \text{ crore}\times 30\%\\ &\quad- ₹40 \text{ crore}\\ &= ₹110 \text{ crore} \end{aligned} \]

This ₹110 crore is an illustrative asset value before any further adjustments for patent litigation, licensing obligations, taxes not already reflected, or other risks not included in the assumptions.

It is not necessarily the value of the entire company or the amount investors should pay for its shares. Enterprise value, equity value, debt, cash, dilution, and transaction-specific rights must be considered separately.

7. Clinical trials, regulatory approval, and valuation risk

The legal status of a biotech product may change its valuation dramatically.

For example, a preclinical drug candidate is exposed to scientific and development uncertainty. A product with successful late-stage clinical trials has more supporting evidence, but it still may face regulatory, manufacturing, commercial, and post-market risks.

A proper valuation should examine:

Clinical-trial authorisations and approvals.

Compliance with applicable ethics and informed-consent requirements.

Adverse-event reporting and data integrity.

Manufacturing quality and inspection findings.

Product approval status in each target market.

Post-market surveillance, recall, and pharmacovigilance obligations.

Restrictions on promotional claims and commercial distribution.

For India, the relevant framework may include the Drugs and Cosmetics Act, 1940, applicable Drugs Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019, depending on the product and activity.

For medical devices, diagnostics, cell therapies, and gene therapies, the precise regulatory classification is critical.

Valuation implication: An approval obtained in one country should not be treated as automatic authorisation to sell in every other jurisdiction.

8. Trade secrets, biological materials, and data ownership

Not every valuable biotech asset is patented. Commercial value may reside in confidential manufacturing processes, cell lines, assay methods, fermentation conditions, algorithms, and proprietary datasets.

Legal due diligence should establish:

Whether confidentiality agreements are enforceable.

Whether employees and contractors have assigned relevant IP.

Whether third-party materials can lawfully be used.

Whether biological materials are subject to transfer restrictions.

Whether clinical data may be lawfully accessed, used, and transferred.

Whether data-protection obligations restrict commercial exploitation.

A trade secret may have considerable value where it provides a sustainable advantage. However, that value may decline if the information becomes public, is independently developed, or cannot be protected effectively.

Biological samples and genetic resources may also be subject to consent, access-and-benefit-sharing, biodiversity, or cross-border transfer requirements. Those restrictions should be assessed under the laws applicable to the sample's origin and intended use.

9. M&A, fundraising, and shareholder disputes

Biotech valuations often determine the allocation of substantial economic rights between founders, investors, licence holders, and acquiring companies.

9.1 Fundraising and securities issuance

Investors may assess valuation using preferred-share rights, liquidation preferences, convertible instruments, milestone-linked financing, and future funding requirements.

A high headline valuation does not necessarily mean founders will receive the same proportion of eventual proceeds. The share-class structure and contractual waterfall may materially change the distribution.

Where Indian company or securities law prescribes valuation or disclosure requirements, the relevant statutory method must be followed rather than relying solely on a negotiated commercial figure.

9.2 Mergers and acquisitions

A biotech acquisition agreement should address:

Ownership and validity of material IP.

Accuracy of clinical and regulatory representations.

Pending patent, employment, and licensing disputes.

Indemnities for pre-closing liabilities.

Earn-outs linked to regulatory approvals or commercial milestones.

Escrow or deferred consideration.

Rights to terminate or adjust consideration if specified conditions fail.

Milestone payments can allocate risk more effectively than treating all projected future revenue as certain at closing.

9.3 Misrepresentation and valuation fraud

A valuation may become legally contentious where management conceals adverse trial results, exaggerates the patent position, fabricates commercial contracts, or materially misstates regulatory progress.

Depending on the facts, potential consequences may arise under company law, securities law, contract law, fraud principles, and applicable criminal law.

A mistaken forecast is not automatically fraud. The relevant questions include what was represented, whether it was materially false or misleading, the knowledge and intent of the parties, reliance, causation, and resulting loss.

10. A practical biotech valuation due-diligence checklist

Valuation review checklist

0 of 12

Corporate and transaction documents

Verify company ownership, share capital, investor rights, and transaction approvals.

Identify any mandatory valuation, disclosure, or independent-review requirements.

Intellectual property

Verify patent ownership, assignments, licences, expiry dates, and litigation.

Assess patentability, enforceability, and freedom-to-operate risks.

Scientific and regulatory evidence

Verify clinical-trial data, product approvals, manufacturing readiness, and quality findings.

Document remaining development milestones, costs, and approval dependencies.

Financial assumptions

Test revenue, pricing, market size, margins, discount rates, and comparable transactions.

Probability-adjust forecasts and avoid double-counting risks.

Contracts and compliance

Review royalty agreements, research contracts, material-transfer agreements, and change-of-control clauses.

Assess data protection, biological-resource restrictions, tax, and related-party issues.

Reporting and governance

Document assumptions, limitations, valuation date, and sensitivity analysis.

Obtain appropriate scientific, legal, financial, and registered-valuer input.

Reset checklistCopy checklist

11. Common legal mistakes in biotech valuation

12. Conclusion

Biotech valuation is both a financial exercise and a legal assessment of the rights, obligations, risks, and commercial opportunities attached to biological technology.

The most important principles are:

Establish ownership and enforceability before assigning substantial value to intellectual property.

Incorporate clinical, regulatory, and manufacturing risks into cash-flow forecasts.

Select a valuation methodology appropriate to the asset's development stage and the transaction's purpose.

Comply with applicable statutory valuation, disclosure, and governance requirements.

Document assumptions and uncertainties so the valuation can withstand investor scrutiny, regulatory review, and litigation.

The Indian Supreme Court's decisions in Novartis and Monsanto, together with the US Supreme Court's decision in Amgen v. Sanofi, illustrate why the legal strength of biotechnology rights can materially affect their economic value.

This is a general legal research overview, not an opinion on a particular transaction. For a real valuation, the governing jurisdiction, asset type, transaction structure, and valuation date should be established first.